Mark N. Wegman Sells 8,500 Shares of BioSpecifics Technologies Corp. (BSTC) Stock
BioSpecifics Technologies Corp. (NASDAQ:BSTC) Director Mark N. Wegman sold 8,500 shares of BioSpecifics Technologies stock in a transaction on Thursday, August 23rd. The stock was sold at an average price of $52.63, for a total value of $447,355.00. Following the transaction, the director now directly owns 76,470 shares of the company’s stock, valued at $4,024,616.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
NASDAQ BSTC opened at $51.78 on Friday. BioSpecifics Technologies Corp. has a fifty-two week low of $38.05 and a fifty-two week high of $54.50. The firm has a market capitalization of $385.10 million, a PE ratio of 26.26 and a beta of 1.45.
BioSpecifics Technologies (NASDAQ:BSTC) last released its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported $0.59 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.10. BioSpecifics Technologies had a return on equity of 19.59% and a net margin of 49.78%. The company had revenue of $7.10 million during the quarter, compared to analysts’ expectations of $7.10 million. equities research analysts anticipate that BioSpecifics Technologies Corp. will post 2.28 EPS for the current year.
Several brokerages recently issued reports on BSTC. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of BioSpecifics Technologies in a report on Thursday, July 5th. BidaskClub raised BioSpecifics Technologies from a “strong sell” rating to a “sell” rating in a report on Friday, June 22nd. Zacks Investment Research raised BioSpecifics Technologies from a “hold” rating to a “strong-buy” rating and set a $62.00 price objective for the company in a report on Tuesday, August 14th. Finally, ValuEngine raised BioSpecifics Technologies from a “sell” rating to a “hold” rating in a report on Thursday, July 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $64.00.
About BioSpecifics Technologies
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names.
Featured Story: Analyst Ratings
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.